PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

• D. C. Dale,
• L. Alsina,
• A. Azar,
• R. Badolato,
• Y. Bertrand,
• A. Deya,
• K. E. Dickerson,
• N. Ezra,
• H. Hasle,
• H. J. Kang,
• S. Kiani-Alikhan,
• T. Kuijpers,
• A. Kulagin,
• D. Langguth,
• C. Levin,
• O. Neth,
• J. Peake,
• C. E. Rutten,
• A. Shcherbina,
• T. K. Tarrant,
• M. G. Vossen,
• C. A. Wysocki,
• A. Belschner,
• D. Cadavid,
• Y. Hu,
• H. Jiang,
• R. MacLeod,
• W. Tang,
• M. Tillinger,
• J. Donadieu

Affiliations

D. C. Dale

1 Department of Medicine, University of Washington, Seattle, United States of America

L. Alsina

2 Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain

A. Azar

3 Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, United States of America

R. Badolato

4 Department of Pediatrics, Angelo Nocivelli Institute of Molecular Medicine, University of Brescia, Brescia, Italy

Y. Bertrand

5 Institute of Pediatric Hematology and Oncology (IHOPe), Civil Hospital of Lyon, Lyon, France

A. Deya

2 Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain

K. E. Dickerson

6 Department of Pediatrics, Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas

N. Ezra

7 California Dermatology Institute, Thousand Oaks, United States of America

H. Hasle

8 Department of Paediatrics, Aarhus University Hospital, Aarhus, Denmark

H. J. Kang

9 Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Wide River Institute of Immunology, Seoul National University Children’s Hospital, Seoul, South Korea

S. Kiani-Alikhan

10 Department of Immunology, Barts Health NHS Trust, London, United Kingdom

T. Kuijpers

11 Department of Paediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, Netherlands

A. Kulagin

12 RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia

D. Langguth

13 Immunology Department, Sullivan Nicolaides Pathology Auchenflower, Queensland, Australia

C. Levin

14 Pediatric Hematology Unit, Emek Medical Center, Afula and the Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa, Israel

O. Neth

15 Pediatric, Infectious Diseases, Rheumatology and Immunology Department, Hospital Virgen del Rocío, Institute of Biomedicine of Seville (IBIS), Seville, Spain

J. Peake

16 Department of Allergy and Immunology, Queensland Children’s Hospital, University of Queensland, South Brisbane, Queensland, Australia

C. E. Rutten

17 Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands

A. Shcherbina

18 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

T. K. Tarrant

19 Division of Rheumatology and Immunology, Department of Medicine, Duke University, Durham, United States of America

M. G. Vossen

20 Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Medical University of Vienna, Vienna, Austria

C. A. Wysocki

21 Division of Allergy and Immunology, Departments of Pediatrics and Internal Medicine, UT Southwestern Medical Center, Dallas

A. Belschner

22 X4 Pharmaceuticals, Boston, United States of America

D. Cadavid

22 X4 Pharmaceuticals, Boston, United States of America

Y. Hu

22 X4 Pharmaceuticals, Boston, United States of America

H. Jiang

22 X4 Pharmaceuticals, Boston, United States of America

R. MacLeod

22 X4 Pharmaceuticals, Boston, United States of America

W. Tang

22 X4 Pharmaceuticals, Boston, United States of America

M. Tillinger

22 X4 Pharmaceuticals, Boston, United States of America

J. Donadieu

23 Service d’Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, France